Eli Lilly Commits Over $1.4 Billion to Advance ALS and Nucleic Acid Therapeutics Through Strategic Partnerships

On May 6, Eli Lilly announced an agreement with UK-based biotech company Alchemab Therapeutics to acquire the UNC5C-targeting antibody ATLX-1282 for up to $415 million, aimed at treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

According to the agreement, Alchemab will lead the Phase I clinical trial of the project, and Eli Lilly will be responsible for subsequent development and commercialization. This is another milestone following the signing of a five-antibody ALS collaboration in January 2025.A further step to consolidate Eli Lilly's layout in the field of neurodegenerative diseases.

ALS Currently Has Only Two Delaying Drugs, with a Median Survival of Less Than 3 Years for Patients. The Introduction of ATLX-1282 Will Enrich Lilly's ALS Pipeline, Which Had Previously Included Antisense Oligonucleotide Therapy (e.g., Acquiring QurAlis' UNC13A Project) and Gene Editing Technology. The Alchemab Platform Can Also Be Extended to Metabolism, Oncology, and Other Fields, and the Upfront Payment from This Collaboration Will Support the Clinical Advancement of Its Multiple Pipelines.

Analysts predict that if ATLX-1282 is approved, its annual sales could exceed $1 billion.Lilly's "Multi-Target + Multi-Technology" Strategy May Lead the $5 Billion ALS Treatment Market by 2030。

In addition to the ALS field,Lilly also "doubled down" on AI + oligonucleotide technology with a deal exceeding $1 billion just 9 days ago (April 29)., Reached a RNA-targeted oligonucleotide drug co-development agreement with Creyon Bio, an American nucleic acid drug research and development company. The collaboration focuses on the discovery, development, and commercialization of novel RNA-targeted oligonucleotide (oligo) drugs for treating various diseases. As part of the collaboration, Creyon will utilize its industry-first artificial intelligence-driven Oligo Engineering engine to design and optimize new drug candidates for targets nominated by Eli Lilly, achieving timelines in nucleic acid drug development that were previously unattainable.

Under the terms of the agreement, Creyon Bio will receive a $13 million upfront payment, which includes cash and the purchase of Creyon Bio equity. If certain milestones are achieved, Creyon Bio is also eligible to receive over $1 billion in development and commercialization payments. Lilly has been granted an exclusive license to lead the candidate pipeline for each target, and if Lilly decides to proceed after achieving certain milestones, it will be responsible for further research, development, and commercialization.

It is worth noting that,This is not Lilly's first foray into the field of oligonucleotide drug development.In June 2024, Eli Lilly introduced QurAlis' investigational ASO drug QRL-204 for the treatment of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), with a potential total deal value of $622 million. In September of the same year, Eli Lilly also reached a $409 million collaboration with Genetic Leap to develop oligonucleotide drugs using the latter's RNA-targeting AI platform, covering "high-priority therapeutic areas."

Lilly has invested heavily in a short period of time, focusing on ALS and AI + oligonucleotide technology, continuously enriching its pipeline through a series of transactions, which is expected to establish a long-term competitive advantage in this field.Its subsequent moves in the transformation of R&D achievements and commercial promotion are worth continuous attention.